Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

The Tie2 receptor antagonist angiopoietin-2 in systemic lupus erythematosus: its correlation with various disease activity parameters.

Salama MK, Taha FM, Safwat M, Darweesh HE, Basel ME.

Immunol Invest. 2012;41(8):864-75. doi: 10.3109/08820139.2012.711407. Epub 2012 Sep 18.

PMID:
22989097
[PubMed - indexed for MEDLINE]
2.

The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.

Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, Schiffer M, Haller H, Witte T.

Ann Rheum Dis. 2009 Oct;68(10):1638-43. doi: 10.1136/ard.2008.094664. Epub 2008 Oct 17.

PMID:
18930996
[PubMed - indexed for MEDLINE]
3.

Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus.

El-Banawy HS, Gaber EW, Maharem DA, Matrawy KA.

J Nephrol. 2012 Jul-Aug;25(4):541-50. doi: 10.5301/jn.5000030.

PMID:
21956768
[PubMed - indexed for MEDLINE]
4.

Vasculitis in systemic lupus erythematosus (SLE)--assessment of peripheral blood mononuclear cell activation and the degree of endothelial dysfunction: initial report.

Kluz J, Kopeć W, Jakobsche U, Prajs I, Adamiec R.

Postepy Hig Med Dosw (Online). 2007 Dec 3;61:725-35.

PMID:
18063917
[PubMed - indexed for MEDLINE]
Free Article
5.

Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.

Heshmat NM, El-Kerdany TH.

Pediatr Allergy Immunol. 2007 Jun;18(4):346-53. Epub 2007 Mar 7.

PMID:
17346298
[PubMed - indexed for MEDLINE]
6.

Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.

Kluz J, Kopeć W, Jakobsche-Policht U, Adamiec R.

Int Angiol. 2009 Jun;28(3):192-201.

PMID:
19506538
[PubMed - indexed for MEDLINE]
7.
8.

Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity.

Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, Abo-Zenah H.

Cytokine. 2006 Aug;35(3-4):148-53. Epub 2006 Oct 5.

PMID:
17027280
[PubMed - indexed for MEDLINE]
9.

Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.

Oelzner P, Deliyska B, Fünfstück R, Hein G, Herrmann D, Stein G.

Clin Rheumatol. 2003 Oct;22(4-5):271-8.

PMID:
14576989
[PubMed - indexed for MEDLINE]
10.

Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Julkunen H, Ekblom-Kullberg S, Miettinen A.

Rheumatol Int. 2012 Aug;32(8):2445-51. doi: 10.1007/s00296-011-1962-3. Epub 2011 Jun 26.

PMID:
21706294
[PubMed - indexed for MEDLINE]
11.

Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.

Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S.

J Rheumatol. 2008 Jul;35(7):1307-13. Epub 2008 May 15.

PMID:
18484695
[PubMed - indexed for MEDLINE]
12.

Soluble adhesion molecules in pediatric rheumatic diseases.

Bloom BJ, Miller LC, Blier PR.

J Rheumatol. 2002 Apr;29(4):832-6.

PMID:
11950029
[PubMed - indexed for MEDLINE]
14.

Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.

Kuryliszyn-Moskal A, Ciolkiewicz M, Klimiuk PA, Sierakowski S.

Scand J Rheumatol. 2009 Jan-Feb;38(1):38-45. doi: 10.1080/03009740802366050.

PMID:
18991188
[PubMed - indexed for MEDLINE]
15.

Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.

Wais T, Fierz W, Stoll T, Villiger PM.

J Rheumatol. 2003 Oct;30(10):2133-9.

PMID:
14528506
[PubMed - indexed for MEDLINE]
16.

Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.

el-Gamal YM, Heshmat NM, el-Kerdany TH, Fawzy AF.

Pediatr Allergy Immunol. 2004 Jun;15(3):270-7.

PMID:
15209962
[PubMed - indexed for MEDLINE]
17.

Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.

Atta MS, Lim KL, Ala'deen DA, Powell RJ, Todd I.

Ann Rheum Dis. 1995 Feb;54(2):117-24.

PMID:
7702398
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement.

Skiljevic D, Jeremic I, Nikolic M, Andrejevic S, Sefik-Bukilica M, Stojimirovic B, Bonaci-Nikolic B.

Clin Chem Lab Med. 2013 May;51(5):1083-91. doi: 10.1515/cclm-2012-0521.

PMID:
23183758
[PubMed - indexed for MEDLINE]
19.

Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.

Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC.

Clin Rheumatol. 1999;18(1):17-22.

PMID:
10088943
[PubMed - indexed for MEDLINE]
20.

Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.

Pradhan VD, Patwardhan MM, Ghosh K.

Indian J Dermatol Venereol Leprol. 2010 Mar-Apr;76(2):145-9. doi: 10.4103/0378-6323.60558.

PMID:
20228543
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk